
Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Agilent Technologies, Inc. (NYSE:A)
6,994.00
Jul-31-2023
Genovis AB (publ.) (OM:GENO) - Form Doc
Business Description: Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Alpha Teknova, Inc. (NasdaqGM:TKNO)
39.23
Jun-30-2023
Alpha Teknova, Inc. (NasdaqGM:TKNO) 2023 Form 10-K
Business Description: Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Bio-Rad Laboratories, Inc. (NYSE:BIO)
2,769.04
Jun-30-2023
Genovis AB (publ.) (OM:GENO) - Form Doc
Business Description: Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
EMD Millipore Corporation
1,709.50
Apr-03-2010
Alpha Teknova, Inc. (NasdaqGM:TKNO) 2023 Form 10-K
Business Description: EMD Millipore Corporation provides research, development, and production of biotechnology and pharmaceutical drug therapies. EMD Millipore Corporation was formerly known as Millipore Corporation and changed its name to EMD Millipore Corporation in July 2010. The company was incorporated in 1954 and is headquartered in Burlington, Massachusetts. EMD Millipore Corporation operates as a subsidiary of Merck KGaA.
Genovis AB (publ.) (OM:GENO)
13.80
Jun-30-2023
Genovis AB (publ.) (OM:GENO) - Form Doc
Business Description: Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; GingisKHAN, a cysteine protease that digests human IgG1; and FabDELLO, a protease that digests human IgG1. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology for site-specific and quantitative conjugation of IgG; TransGLYCIT, a platform technology that enables site-specific human IgG glycan remodeling; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase hydrolyzing the amide bond between the polypeptide asparagine and the innermost GlcNAc; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of α-Fucosidases; GalactEXO, a β-Galactosidase mix; GalNAcEXO, an α-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin for purification of mucin-type O-glycosylated proteins and peptides; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
Hardy Diagnostics, Inc.
49.10
-
Alpha Teknova, Inc. (NasdaqGM:TKNO) 2023 Form 10-K
Business Description: Hardy Diagnostics, Inc. is a health care supplies company. It was formerly known as Hardy Media Inc. and changed its name to Hardy Diagnostics, Inc. in January 1992. It was founded in 1980 and is headquartered in Santa Maria, California.
Lonza Group AG (SWX:LONN)
7,021.35
Jun-30-2023
Alpha Teknova, Inc. (NasdaqGM:TKNO) 2023 Form 10-K
Business Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
New England Biolabs Inc.
1.79
-
Genovis AB (publ.) (OM:GENO) - Form Doc
Business Description: New England Biolabs Inc. is engaged in the discovery, development, and commercialization of recombinant and native enzymes for genomic research. Its products include restriction endonucleases, DNA modifying enzymes, library preparation for next generation sequencing, nucleic acid purification, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein expression and purification technologies, protein tools, glycobiology, DNA plasmids, buffers, and strains; DNA assembly, cloning, and mutagenesis kits; custom ready panels; and PCR, polymerases, and amplification technologies. The company’s services include freezer programs, customized solutions and OEM, business development opportunities, collaboration, and licensing. Its products are used in cloning and synthetic biology, DNA amplification and PCR, DNA modification, RNA analysis, library preparation for next generation sequencing, epigenetics, protein expression and purification, protein analysis and tools, glycobiology, and cellular analysis applications. The company offers its products through a worldwide network of distributors, affiliates, and its subsidiaries. New England Biolabs Inc. was founded in 1974 and is based in Ipswich, Massachusetts with additional offices in Hitchin, United Kingdom; and Whitby, Canada.
Repligen Corporation (NasdaqGS:RGEN)
729.33
Jun-30-2023
Repligen Corporation (NasdaqGS:RGEN) 2023 Form 10-K
Business Description: Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Sartorius Aktiengesellschaft (XTRA:SRT3)
4,074.51
Jun-30-2023
Repligen Corporation (NasdaqGS:RGEN) 2023 Form 10-K
Business Description: Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. It offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, as well as software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and membrane filters, glass and quartz microfibre filters, syringeless and in-line filters, lab chromatography, and filters and blotting papers. The company also provides live-cell analysis systems, reagents and consumables, and live-cell imaging and analysis software; equipment manufacturer membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and detection systems, sensor chips and consumables, systems, biosensors and kits, compliance tools, and systems software. Further, it offers water purification systems; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, it provides bioprocess consulting and engineering, media and process, instrument, system service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
Sigma-Aldrich Corporation
2,781.00
Sep-30-2015
Repligen Corporation (NasdaqGS:RGEN) 2023 Form 10-K
Business Description: Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. It offers products in the areas of analytical chemistry, cell culture and analysis, chemistry and biochemicals, clinical and diagnostics, filtration, industrial microbiology, labware, materials science, molecular biology and functional genomics, mRNA development and manufacturing, pharma and biopharma manufacturing, protein biology, and water purification. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing. The company also manufactures meglumine, an amino sugar derived from glucose and a component of medical imaging contrast media. It sells its products to pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies, and hospitals. The company was founded in 1951 and is based in Burlington, Massachusetts with additional offices worldwide. Sigma-Aldrich Corporation operates as a subsidiary of MERCK Kommanditgesellschaft auf Aktien.
Thermo Fisher Scientific Inc. (NYSE:TMO)
43,524.00
Jul-01-2023
Genovis AB (publ.) (OM:GENO) - Form Doc
Business Description: Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
*denotes proprietary relationship